Evolution  ||| S:0 E:10 ||| NN
from  ||| S:10 E:15 ||| IN
double  ||| S:15 E:22 ||| JJ
to  ||| S:22 E:25 ||| TO
triple-antimalarial  ||| S:25 E:45 ||| JJ
drug  ||| S:45 E:50 ||| NN
combinations  ||| S:50 E:63 ||| NN
Drug  ||| S:63 E:68 ||| NN
combinations  ||| S:68 E:81 ||| NNS
are  ||| S:81 E:85 ||| VBP
used  ||| S:85 E:90 ||| VBN
to  ||| S:90 E:93 ||| TO
treat  ||| S:93 E:99 ||| VB
multiple-drug  ||| S:99 E:113 ||| JJ
resistant  ||| S:113 E:123 ||| JJ
malaria  ||| S:123 E:131 ||| NN
parasites  ||| S:131 E:141 ||| NNS
and  ||| S:141 E:145 ||| CC
to  ||| S:145 E:148 ||| TO
attempt  ||| S:148 E:156 ||| VB
to  ||| S:156 E:159 ||| TO
further  ||| S:159 E:167 ||| RB
delay  ||| S:167 E:173 ||| VB
the  ||| S:173 E:177 ||| DT
evolution  ||| S:177 E:187 ||| NN
of  ||| S:187 E:190 ||| IN
drug  ||| S:190 E:195 ||| NN
resistance ||| S:195 E:205 ||| NN
.  ||| S:205 E:207 ||| .
Most  ||| S:207 E:212 ||| RBS
current  ||| S:212 E:220 ||| JJ
antimalarial  ||| S:220 E:233 ||| JJ
combinations  ||| S:233 E:246 ||| NNS
are  ||| S:246 E:250 ||| VBP
binary  ||| S:250 E:257 ||| VBN
but  ||| S:257 E:261 ||| CC
it  ||| S:261 E:264 ||| PRP
is  ||| S:264 E:267 ||| VBZ
likely  ||| S:267 E:274 ||| RB
that  ||| S:274 E:279 ||| IN
new  ||| S:279 E:283 ||| JJ
triple  ||| S:283 E:290 ||| JJ
drug  ||| S:290 E:295 ||| NN
combinations  ||| S:295 E:308 ||| NNS
will  ||| S:308 E:313 ||| MD
be  ||| S:313 E:316 ||| VB
required  ||| S:316 E:325 ||| VBN
in  ||| S:325 E:328 ||| IN
the  ||| S:328 E:332 ||| DT
future ||| S:332 E:338 ||| NN
.  ||| S:338 E:340 ||| .
A  ||| S:340 E:342 ||| DT
review  ||| S:342 E:349 ||| NN
of  ||| S:349 E:352 ||| IN
previous  ||| S:352 E:361 ||| JJ
triple  ||| S:361 E:368 ||| JJ
combinations  ||| S:368 E:381 ||| NNS
of  ||| S:381 E:384 ||| IN
antimalarial  ||| S:384 E:397 ||| JJ
drugs  ||| S:397 E:403 ||| NNS
was  ||| S:403 E:407 ||| VBD
done  ||| S:407 E:412 ||| VBN
to  ||| S:412 E:415 ||| TO
focus  ||| S:415 E:421 ||| VB
attention  ||| S:421 E:431 ||| NN
on  ||| S:431 E:434 ||| IN
past  ||| S:434 E:439 ||| JJ
problems  ||| S:439 E:448 ||| NNS
and  ||| S:448 E:452 ||| CC
possible  ||| S:452 E:461 ||| JJ
future  ||| S:461 E:468 ||| JJ
combinations ||| S:468 E:480 ||| NNS
.  ||| S:480 E:482 ||| .
The  ||| S:482 E:486 ||| DT
advantages  ||| S:486 E:497 ||| NNS
of  ||| S:497 E:500 ||| IN
such  ||| S:500 E:505 ||| JJ
triple  ||| S:505 E:512 ||| JJ
drug  ||| S:512 E:517 ||| NN
combinations  ||| S:517 E:530 ||| NNS
include  ||| S:530 E:538 ||| VBP
greater  ||| S:538 E:546 ||| JJR
efficacy  ||| S:546 E:555 ||| NN
against  ||| S:555 E:563 ||| IN
multiple-drug  ||| S:563 E:577 ||| JJ
resistant  ||| S:577 E:587 ||| JJ
strains ||| S:587 E:594 ||| NNS
,  ||| S:594 E:596 ||| ,
synergistic  ||| S:596 E:608 ||| JJ
action  ||| S:608 E:615 ||| NN
between  ||| S:615 E:623 ||| IN
the  ||| S:623 E:627 ||| DT
different  ||| S:627 E:637 ||| JJ
medications  ||| S:637 E:649 ||| NN
and  ||| S:649 E:653 ||| CC
simplification  ||| S:653 E:668 ||| NN
of  ||| S:668 E:671 ||| IN
the  ||| S:671 E:675 ||| DT
regimen  ||| S:675 E:683 ||| NN
so  ||| S:683 E:686 ||| RB
that  ||| S:686 E:691 ||| IN
it  ||| S:691 E:694 ||| PRP
could  ||| S:694 E:700 ||| MD
be  ||| S:700 E:703 ||| VB
administered  ||| S:703 E:716 ||| VBN
under  ||| S:716 E:722 ||| IN
direct  ||| S:722 E:729 ||| JJ
observation  ||| S:729 E:741 ||| NN
and  ||| S:741 E:745 ||| CC
possibly  ||| S:745 E:754 ||| RB
as  ||| S:754 E:757 ||| IN
single-dose  ||| S:757 E:769 ||| JJ
therapy ||| S:769 E:776 ||| NN
.  ||| S:776 E:778 ||| .
The  ||| S:778 E:782 ||| DT
disadvantages  ||| S:782 E:796 ||| NN
of  ||| S:796 E:799 ||| IN
poly-pharmacy  ||| S:799 E:813 ||| NNS
include  ||| S:813 E:821 ||| VBP
increased  ||| S:821 E:831 ||| VBN
cost  ||| S:831 E:836 ||| NN
of  ||| S:836 E:839 ||| IN
medication ||| S:839 E:849 ||| NN
,  ||| S:849 E:851 ||| ,
difficulty  ||| S:851 E:862 ||| NN
preparing  ||| S:862 E:872 ||| VBG
robust  ||| S:872 E:879 ||| JJ
regulatory  ||| S:879 E:890 ||| JJ
packages  ||| S:890 E:899 ||| NNS
and  ||| S:899 E:903 ||| CC
problems  ||| S:903 E:912 ||| NNS
constructing  ||| S:912 E:925 ||| VBP
combined  ||| S:925 E:934 ||| VBN
formulations  ||| S:934 E:947 ||| JJ
due  ||| S:947 E:951 ||| JJ
to  ||| S:951 E:954 ||| TO
drug-drug  ||| S:954 E:964 ||| JJ
interactions ||| S:964 E:976 ||| NNS
.  ||| S:976 E:978 ||| .
Given  ||| S:978 E:984 ||| VBN
the  ||| S:984 E:988 ||| DT
arrival  ||| S:988 E:996 ||| NN
of  ||| S:996 E:999 ||| IN
artemisinin  ||| S:999 E:1011 ||| JJ
tolerance ||| S:1011 E:1020 ||| NN
/ ||| S:1020 E:1021 ||| CD
resistance  ||| S:1021 E:1032 ||| NN
in  ||| S:1032 E:1035 ||| IN
Southeast  ||| S:1035 E:1045 ||| NNP
Asia ||| S:1045 E:1049 ||| NNP
,  ||| S:1049 E:1051 ||| ,
it  ||| S:1051 E:1054 ||| PRP
is  ||| S:1054 E:1057 ||| VBZ
likely  ||| S:1057 E:1064 ||| RB
that  ||| S:1064 E:1069 ||| IN
new  ||| S:1069 E:1073 ||| JJ
drugs  ||| S:1073 E:1079 ||| NNS
introduced  ||| S:1079 E:1090 ||| VBN
for  ||| S:1090 E:1094 ||| IN
malaria  ||| S:1094 E:1102 ||| JJ
treatment  ||| S:1102 E:1112 ||| NN
will  ||| S:1112 E:1117 ||| MD
be  ||| S:1117 E:1120 ||| VB
in  ||| S:1120 E:1123 ||| IN
triple  ||| S:1123 E:1130 ||| JJ
drug  ||| S:1130 E:1135 ||| NN
combinations ||| S:1135 E:1147 ||| NNS
.  ||| S:1147 E:1149 ||| .
